Please wait while the formulary information is being retrieved.
BEVITROL (lipase/protease/amylase)
- exocrine pancreatic insufficiency
9,000-112,500-112,500 unit capsule
- Dosage information is not available
- acarbose
- Glyset
- miglitol
- Precose
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Gastrointestinal obstruction
- Meconium ileus
Severe
Moderate
- Crohn's disease
- Fibrosing colonopathy
- Gastrointestinal tract surgery
- Gout
- Hyperuricemia
- Short bowel syndrome
BEVITROL (lipase/protease/amylase)
- exocrine pancreatic insufficiency
- None
- None
More Frequent
Severe
Less Severe
- Abdominal pain with cramps
- Abdominal distension
- Cough
- Dizziness
- Flatulence
- Headache disorder
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Biliary calculus
- Diarrhea
- Disorder of the digestive system
- Fibrosing colonopathy
- Gastrointestinal obstruction
- Hyperuricemia
- Nausea
Less Severe
- Pruritus ani
- Pruritus of skin
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Amylase
- Severity Level:
C
- Additional Notes: Fda category c in combo products
Lipase
- Severity Level:
C
- Additional Notes: Insufficient data available; consider maternal treatment benefit vs. fetal risk
Protease
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Amylase
Insufficient human data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
Lipase
Insufficient human data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail;Consider maternal treatment benefit vs possible infant risk |
Protease
Insufficient human data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Exocrine pancreatic insufficiency | |
| K86.81 | Exocrine pancreatic insufficiency |
| K90.3 | Pancreatic steatorrhea |
| 0-9 | A-Z |
|---|---|
| K86.81 | Exocrine pancreatic insufficiency |
| K90.3 | Pancreatic steatorrhea |
Formulary Reference Tool